Cancer Res Treat.  2025 Jan;57(1):198-211. 10.4143/crt.2024.382.

Fecal Microbial Dysbiosis Is Associated with Colorectal Cancer Risk in a Korean Population

• Kim J
• Gunathilake M
• Yeo HY
• Oh JH
• Kim BC
• Han N
• Kim B
• Pyun H
• Lim MY
• Nam YD
• Chang HJ

• KMID: 2564594
• DOI: http://doi.org/10.4143/crt.2024.382

Abstract

Purpose
The association between the fecal microbiota and colorectal cancer (CRC) risk has been suggested in epidemiologic studies. However, data from large-scale population-based studies are lacking.
Materials and Methods
In this case-control study, we recruited 283 CRC patients from the Center for Colorectal Cancer, National Cancer Center Hospital, Korea to perform 16S rRNA gene sequencing of fecal samples. A total of 283 age- and sex-matched healthy participants were selected from 890 cohort of healthy Koreans that are publicly available (PRJEB33905). The microbial dysbiosis index (MDI) was calculated based on the differentially abundant species. The association between MDI and CRC risk was observed using conditional logistic regression. Sparse Canonical Correlation Analysis was performed to integrate species data with microbial pathways obtained by PICRUSt2.
Results
There is a significant divergence of the microbial composition between CRC patients and controls (permutational multivariate analysis of variance p=0.001). Those who were in third tertile of the MDI showed a significantly increased risk of CRC in the total population (odds ratio [OR], 6.93; 95% confidence interval [CI], 3.98 to 12.06; p-trend < 0.001) compared to those in the lowest tertile. Similar results were found for men (OR, 6.28; 95% CI, 3.04 to 12.98; p-trend < 0.001) and women (OR, 7.39; 95% CI, 3.10 to 17.63; p-trend < 0.001). Bacteroides coprocola and Bacteroides plebeius species and 12 metabolic pathways were interrelated in healthy controls that explain 91% covariation across samples.
Conclusion
Dysbiosis in the fecal microbiota may be associated with an increased risk of CRC. Due to the potentially modifiable nature of the gut microbiota, our findings may have implications for CRC prevention among Koreans.

Keyword

Fecal microbiome; 16S rRNA gene sequencing; Microbial dysbiosis; Microbial metabolic pathways; Colorectal neoplasms

Figure

• 

  Fig. 1. (A) Comparison of alpha diversity indices based on anatomical sites. (B) Based on cancer stage. (C) Principal coordinate analysis plot of the weighted UniFrac distance. Red indicates colorectal cancer cases and blue indicates healthy controls.

• 

  Fig. 2. (A) Statistical analysis of taxonomic and functional profiles (STAMP) results plot for taxonomic phylum STAMP results plots for colon cancer (B) and rectal cancer (C) at phylum level.

• 

  Fig. 3. Enterotypes identified from the microbial composition of colorectal cancer cases.

• 

  Fig. 4. Comparison of microbial dysbiosis index between each anatomical sites of colorectal cancer cases and controls. (A) Total population. (B) Each sex. (C) Across cancer stages. (D) Across cancer stages by sex.

• 

  Fig. 5. Community detection based on greedy optimization of modularity of the network.

Reference

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209–49.

2. Murphy N, Moreno V, Hughes DJ, Vodicka L, Vodicka P, Aglago EK, et al. Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Mol Aspects Med. 2019; 69:2–9.

3. World Cancer Research Fund, American Institute for Cancer Research. Continuous Update Project Report: diet, nutrition, physical activity and colorectal cancer. London: World Cancer Research Fund International;2018.

4. Sawicki T, Ruszkowska M, Danielewicz A, Niedzwiedzka E, Arlukowicz T, Przybylowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers (Basel). 2021; 13:2025.

5. Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Front Immunol. 2020; 11:615056.

6. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019; 16:690–704.

7. O’Keefe SJ. Nutrition and colonic health: the critical role of the microbiota. Curr Opin Gastroenterol. 2008; 24:51–8.

8. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol. 2012; 10:323–35.

9. Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, et al. Fecal microbiota, fecal metabolome, and colorectal cancer interrelations. PLoS One. 2016; 11:e0152126.

10. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009; 457:480–4.

11. McHardy IH, Goudarzi M, Tong M, Ruegger PM, Schwager E, Weger JR, et al. Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. Microbiome. 2013; 1:17.

12. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012; 22:292–8.

13. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012; 22:299–306.

14. Young C, Wood HM, Seshadri RA, Van Nang P, Vaccaro C, Melendez LC, et al. The colorectal cancer-associated faecal microbiome of developing countries resembles that of developed countries. Genome Med. 2021; 13:27.

15. Berg G, Rybakova D, Fischer D, Cernava T, Verges MC, Charles T, et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome. 2020; 8:103.

16. Lim MY, Hong S, Bang SJ, Chung WH, Shin JH, Kim JH, et al. Gut microbiome structure and association with host factors in a Korean population. mSystems. 2021; 6:e0017921.

17. Package ‘MatchIt’ October 12, 2023, version 4.5.5 [Internet]. Vienna: R Foundation for Statistical Computing;2023. [cited 2023 Sep 20]. Available from: https://cran.r-project.org/web/packages/MatchIt/MatchIt.pdf.

18. Park SS, Kim B, Kim MJ, Roh SJ, Park SC, Kim BC, et al. The effect of curative resection on fecal microbiota in patients with colorectal cancer: a prospective pilot study. Ann Surg Treat Res. 2020; 99:44–51.

19. QIIME [Internet]. QIIME;2023. [cited 2023 Sep 20]. Available from: http://qiime.org/.

20. Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics. 2014; 30:3123–4.

21. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011; 473:174–80.

22. Wei S, Bahl MI, Baunwall SM, Hvas CL, Licht TR. Determining gut microbial dysbiosis: a review of applied indexes for assessment of intestinal microbiota imbalances. Appl Environ Microbiol. 2021; 87:e00395–21.

23. Kim MJ, Jung DR, Lee JM, Kim I, Son H, Kim ES, et al. Microbial dysbiosis index for assessing colitis status in mouse models: a systematic review and meta-analysis. iScience. 2024; 27:108657.

24. Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014; 15:382–92.

25. Liu W, Zhang R, Shu R, Yu J, Li H, Long H, et al. Study of the relationship between microbiome and colorectal cancer susceptibility using 16SrRNA sequencing. Biomed Res Int. 2020; 2020:7828392.

26. Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013; 105:1907–11.

27. Carson TL, Byrd DA, Smith KS, Carter D, Abaskaron M, Little RB, et al. A case-control study of the association between the gut microbiota and colorectal cancer: exploring the roles of diet, stress, and race. Gut Pathog. 2024; 16:13.

28. Sheng Q, Du H, Cheng X, Cheng X, Tang Y, Pan L, et al. Characteristics of fecal gut microbiota in patients with colorectal cancer at different stages and different sites. Oncol Lett. 2019; 18:4834–44.

29. Gao R, Kong C, Li H, Huang L, Qu X, Qin N, et al. Dysbiosis signature of mycobiota in colon polyp and colorectal cancer. Eur J Clin Microbiol Infect Dis. 2017; 36:2457–68.

30. Amiot A, Dona AC, Wijeyesekera A, Tournigand C, Baumgaertner I, Lebaleur Y, et al. (1)H NMR spectroscopy of fecal extracts enables detection of advanced colorectal neoplasia. J Proteome Res. 2015; 14:3871–81.

31. Mira-Pascual L, Cabrera-Rubio R, Ocon S, Costales P, Parra A, Suarez A, et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J Gastroenterol. 2015; 50:167–79.

32. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012; 6:320–9.

33. Yang J, McDowell A, Kim EK, Seo H, Lee WH, Moon CM, et al. Development of a colorectal cancer diagnostic model and dietary risk assessment through gut microbiome analysis. Exp Mol Med. 2019; 51:1–15.

34. Liu J, Huang X, Chen C, Wang Z, Huang Z, Qin M, et al. Identification of colorectal cancer progression-associated intestinal microbiome and predictive signature construction. J Transl Med. 2023; 21:373.

35. Yang TW, Lee WH, Tu SJ, Huang WC, Chen HM, Sun TH, et al. Enterotype-based analysis of gut microbiota along the conventional adenoma-carcinoma colorectal cancer pathway. Sci Rep. 2019; 9:10923.

36. Du X, Li Q, Tang Z, Yan L, Zhang L, Zheng Q, et al. Alterations of the gut microbiome and fecal metabolome in colorectal cancer: implication of intestinal metabolism for tumorigenesis. Front Physiol. 2022; 13:854545.

37. He T, Cheng X, Xing C. The gut microbial diversity of colon cancer patients and the clinical significance. Bioengineered. 2021; 12:7046–60.

38. Pei T, Zhu D, Yang S, Hu R, Wang F, Zhang J, et al. Bacteroides plebeius improves muscle wasting in chronic kidney disease by modulating the gut-renal muscle axis. J Cell Mol Med. 2022; 26:6066–78.

39. King M, Hurley H, Davidson KR, Dempsey EC, Barron MA, Chan ED, et al. The link between fusobacteria and colon cancer: a fulminant example and review of the evidence. Immune Netw. 2020; 20:e30.

40. Iadsee N, Chuaypen N, Techawiwattanaboon T, Jinato T, Patcharatrakul T, Malakorn S, et al. Identification of a novel gut microbiota signature associated with colorectal cancer in Thai population. Sci Rep. 2023; 13:6702.

41. Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013; 66:462–70.

42. Yuan B, Ma B, Yu J, Meng Q, Du T, Li H, et al. Fecal bacteria as non-invasive biomarkers for colorectal adenocarcinoma. Front Oncol. 2021; 11:664321.

43. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009; 15:1183–9.

44. Khattab RH, Abo-Hammam RH, Salah M, Hanora AM, Shabayek S, Zakeer S. Multi-omics analysis of fecal samples in colorectal cancer Egyptians patients: a pilot study. BMC Microbiol. 2023; 23:238.

45. Zhao M, Chu J, Feng S, Guo C, Xue B, He K, et al. Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: a review. Biomed Pharmacother. 2023; 164:114985.

46. Artemev A, Naik S, Pougno A, Honnavar P, Shanbhag NM. The association of microbiome dysbiosis with colorectal cancer. Cureus. 2022; 14:e22156.

47. Tester RF, Al-Ghazzewi FH. Mannans and health, with a special focus on glucomannans. Food Res Int. 2013; 50:384–91.

48. Xu D, Ma M, Liu Y, Zhou T, Wang K, Deng Z, et al. PreQ0 base, an unusual metabolite with anti-cancer activity from Streptomyces qinglanensis 172205. Anticancer Agents Med Chem. 2015; 15:285–90.

49. Mollick T, Lain S. Modulating pyrimidine ribonucleotide levels for the treatment of cancer. Cancer Metab. 2020; 8:12.

50. Mosca L, Pagano M, Pecoraro A, Borzacchiello L, Mele L, Cacciapuoti G, et al. S-Adenosyl-l-methionine overcomes uL3-mediated drug resistance in p53 deleted colon cancer cells. Int J Mol Sci. 2020; 22:103.

51. Huh JW, Kim MJ, Kim J, Lee HG, Ryoo SB, Ku JL, et al. Enterotypical Prevotella and three novel bacterial biomarkers in preoperative stool predict the clinical outcome of colorectal cancer. Microbiome. 2022; 10:203.

52. Calderon-Perez L, Llaurado E, Companys J, Pla-Paga L, Pedret A, Rubio L, et al. Interplay between dietary phenolic compound intake and the human gut microbiome in hypertension: a cross-sectional study. Food Chem. 2021; 344:128567.